Clinical trials: Cancer Disease Progression
NSCLC Stage IV
Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer
Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
- Trial name
- MWA in NSCLC (NCT04102982)
- Testing
- Camrelizumab, Camrelizumab plus microwave ablation
- Where
- 13 sites in China
- Volunteers
- 200 people
- Sponsor
- Shandong Provincial Hospital
Advanced Renal Cell Carcinoma (aRCC)
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Introduction: This document explains a clinical research study conducted at Peking Union Medical College Hospital. The study aims to evaluate a new combination treatment - Envafolimab (an immunotherapy) and Axitinib (a targeted…
- Trial name
- NCT07159191
- Testing
- Envafolimab Injection, Axitinib Tablets
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Diffuse Large B-cell Lymphoma
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.
- Trial name
- NCT05257018
- Testing
- R-CDOP+intrathecal MTX
- Where
- 2 sites in China
- Volunteers
- 83 people
- Sponsor
- Fudan University
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence, Progression of Bladder Cancer, Transurethral Resection of Bladder Tumor
- Trial name
- NCT07589413
- Testing
- Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhiping Wang
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Cancer
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
This was a randomized, open-label, multi-center Phase III study evaluating the efficacy and safety of lapatinib in combination with trastuzumab versus trastuzumab alone as continued HER2 suppression therapy in women with…
- Trial name
- NCT00968968
- Testing
- Lapatinib, Trastuzumab
- Where
- 116 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Glioma of Brain
Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy
Background: Infiltrative low grade gliomas (LGGs) are the most common primary central nervous system malignancies excluding the highest grade glioma, glioblastoma multiforme.
- Trial name
- NCT03534050
- Testing
- postoperative adjuvant RT
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Mesothelioma, Malignant
Niraparib Efficacy in Patient With Unresectable Mesothelioma
Multicentre, 2 arm, open-label UK randomised phase II trial to determine the efficacy of niraparib versus active symptom control (ASC) in patients who have relapsed after previously receiving platinum based systemic therapy.
- Trial name
- NERO (NCT05455424)
- Testing
- Niraparib Oral Product, Active Symptom Control
- Where
- 11 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Glioblastoma
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is associated with poor prognosis despite standard treatment with maximal safe resection followed by radiotherapy plus temozolomide (the Stupp…
- Trial name
- ELITE (NCT07758062)
- Testing
- Levetiracetam Extended-Release Granules, Temozolomide (TMZ), Radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Tianjin Medical University General Hospital
Hepatocellular Carcinoma (HCC)
Computer Guided Microwave Liver Ablation
The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults.
- Trial name
- MWA Sim (NCT07226869)
- Testing
- Computer-Assisted Microwave Liver Ablation
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- NE Scientific INC
Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases
Keynatinib in Treated Patients With NSCLC and Brain Metastases
The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or progression of brain metastasis after treatment with…
- Trial name
- NCT04824079
- Testing
- Keynatinib
- Where
- 5 sites in China
- Volunteers
- 16 people
- Sponsor
- Medolution Ltd.
Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
The goal of this phase II randomized controlled clinical trial is to evaluate whether adding lubiprostone to standard postoperative maintenance therapy can delay disease progression and recurrence in adult patients with…
- Conditions
- Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis, Colorectal Cancer (CRC)
- Trial name
- NCT07405736
- Testing
- maintenance therapy plus lubiprostone, maintenance therapy
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Lung Neoplasms, Progression
Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer
Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and…
- Trial name
- NCT06409416
- Testing
- Analysis of diagnostic biomarkers
- Volunteers
- 20 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Kaposi Sarcoma, Progression, Disease
Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma
Classic and endemic Kaposi's sarcoma (KS) are lymphangio-proliferations associated with human herpes virus 8 (HHV8), which treatment is poorly codified. Chemotherapies give at best 30-60% of transient responses.
- Trial name
- KAPKEY (NCT03469804)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sturge-Weber Syndrome
Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome
This study has three aims that hope to expand the knowledge on the cause of Sturge-Weber Syndrome (SWS) and improve clinical care of Sturge-Weber Syndrome patients.
- Trial name
- NCT01425944
- Where
- 7 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Ovarian Cancer
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful adding investigational drug cediranib to olaparib after disease progression on olaparib alone in patients with ovarian cancer.
- Trial name
- NCT02340611
- Testing
- Olaparib, Cediranib
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma, Face Cancer
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) has been the standard treatment modality for HCC aiming at clinical cure.
- Trial name
- NCT01833299
- Testing
- TACE-Sorafenib group, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
This study is designed to compare long-term outcomes among patients randomized on the BMT CTN 0702 protocol (NCT01109004), "A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous…
- Trial name
- NCT02322320
- Testing
- Lenalidomide
- Where
- 42 sites in United States
- Volunteers
- 273 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen.
- Trial name
- AMAZE-lung (NCT05601973)
- Testing
- Amivantamab, Lazertinib, Zirabev
- Where
- 18 sites in France, Italy and 4 more
- Volunteers
- 60 people
- Sponsor
- ETOP IBCSG Partners Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.